PFBT
LTRN icon

Parkside Financial Bank & Trust’s Lantern Pharma LTRN Stock Holding History

Parkside Financial Bank & Trust’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-260
Closed -$822 – 2767
2025
Q2 		$822 Hold
260
– – ﹤0.01% 2331
2025
Q1 		$921 Hold
260
– – ﹤0.01% 2140
2024
Q4 		$830 Hold
260
– – ﹤0.01% 1775
2024
Q3 		$955 Buy
+260
New +$1.07K ﹤0.01% 1718

Other funds holding LTRN

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Parkside Financial Bank & Trust's LTRN Position: Q3 2025 in Review

Parkside Financial Bank & Trust sold out of Lantern Pharma (LTRN) in Q3 2025, closing a stake of 260 shares — an estimated $822 sold.

Parkside Financial Bank & Trust first reported a position in LTRN in Q3 2024 and held it in 4 quarters. The position peaked at $955 in Q3 2024. 30 funds tracked by Wall St. Rank hold LTRN as of Q3 2025.

  • Parkside Financial Bank & Trust reported no remaining Lantern Pharma position as of Q3 2025 after selling out during the quarter.
  • Parkside Financial Bank & Trust sold 260 Lantern Pharma shares in Q3 2025, an estimated $822.
  • Parkside Financial Bank & Trust first reported a position in Lantern Pharma in Q3 2024 and held it in 4 quarters.
  • Parkside Financial Bank & Trust's Lantern Pharma position peaked at $955 in Q3 2024.
  • 30 funds tracked by Wall St. Rank held Lantern Pharma as of Q3 2025.

Based on Parkside Financial Bank & Trust's 13F filing for Q3 2025, filed 30 Oct 2025.